About Careers MedBlog Contact us
Fluorescing Proteins From Deep Sea Creatures To Aid Cancer Immunotherapy

Fluorescing Proteins From Deep Sea Creatures To Aid Cancer Immunotherapy

Written by Anjali Aryamvally, B.Tech (Genetic Engineering)
Article Reviewed by 
The Medindia Medical Review Team on January 11, 2018 at 4:24 PM
Font : A-A+

  • Novel luciferase enzyme from marine dwellers allows to develop Matador assay which can track efficacy of cancer therapies.
  • The florescence producing luciferases are released by dead and dying cells and can be measured quantitatively.
  • The assay is highly sensitive, specific, rapid, and can be performed in a single step without the need for expensive equipment.

A novel luciferase enzyme has been used in the development of a cytotoxic assay to determine cell death, shows study from the Keck School of Medicine of USC. The enzyme, extracted from deep sea dwellers is responsible for bioluminescence, giving these creatures their glow. Using this particular property of the enzyme, the team has developed the Matador assay which is used to measure cell death. The cytotoxic assay may allow to track progression of cancer immunotherapies by allowing oncologists to visualize if the therapy was successful in killing the cancer cells. The study is published in the journal Scientific Reports.

Testing cancer immunotherapies

While cancer immunotherapies including chimeric antigen receptor-T (CAR-T) cells are the most promising areas in cancer research, these are also the most difficult due to limited testing methods. Testing methods are critical to determine if the cancer therapy was successful in killing cancer cells.

Listen to this article

Fluorescing Proteins From Deep Sea Creatures To Aid Cancer Immunotherapy

"Radioactive chromium release assay is the gold standard for testing whether an immunotherapy kills cancer cells. This method is expensive, complicated and requires special disposal practices," says co-author Preet M. Chaudhary, MD, PhD, professor of medicine at the Keck School.

The hazards associated with the harmful effects of radioactivity and disposal of that radioactive waste prompt researchers to look for other safer alternatives for testing efficacy of cancer therapies.

Matador assay

The novel cytotoxicity assay involves expression of the luciferase enzyme in target cells. It is incorporated in such a manner that only healthy cells can retain the enzyme; dead or dying cells release the compound and as a result produce fluorescence. The released fluorescence can be measured using a luminometer and gives an idea of how many cells are getting killed and where.

"In our hands, the Matador assay can detect cell death in as little as 30 minutes, which can ultimately translate to more expedient treatments for patients getting cellular immunotherapies such as CAR-T cells," Chaudhary says.

"It could potentially play a role in screening other types of anticancer agents or even measuring environmental toxins."

To validate the ability to detect cytotoxicity, more than 80 cell lines were created that stably expressed luciferase in the cytosol. The study did not come across any cell line in which the Matador assay did not work as expected. In all the cell lines, there was significant increase in the luciferase activity upon induction of cell death.

Highlights of the assay:
  • Highly sensitive, specific and fast
  • Does not require expensive equipment
  • Detects cell death at a single cell level
  • Luciferase is highly thermostable
  • Luciferases retain their activity even after thawing and freezing
References :
  1. Matta, H. et al. Development and characterization of a novel luciferase based cytotoxicity assay. Scientific Reports 8, (2018).
Source: Medindia

Citations   close


Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Fluorescing Proteins From Deep Sea Creatures To Aid Cancer Immunotherapy Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests